Lovastatin Tablet
Product Images NDC 70518-2425

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Lovastatin (NDC 70518-2425). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Lovastatin Tablet 40 mg Quantity: 90 Tablets This text provides important information about a Lovastatin Tablet, including the strength (40 mg), quantity (90 Tablets), NDC number, expiry details, manufacturer details, storage instructions, and dosage recommendation. The tablet is white and round, and the usual dosage instructions can be found in the insert. It is specified to keep the medication out of reach of children and store it within the recommended temperature range. The tablet has been repackaged by RemedyRepack Inc. and manufactured by Carlsbad Tech. Inc.*

FDA Label Image

Structural Formula (Lov00 0004 01)

FDA Label Image

Table I (Lov00 0004 02)

FDA Label Image

Figure 1 (Lov00 0004 03)

This text provides a visual representation (Figure 1) displaying the proportion of participants without acute major coronary events over the years of follow-up (1, 2, 3, 4). It specifically focuses on the primary endpoint of the study.*

FDA Label Image

Table Vii (Lov00 0005 04)

The text provides a table listing drug interactions associated with an increased risk of myopathy/rhabdomyolysis. It includes prescribing recommendations for various medications, such as avoiding certain drugs with lovastatin, not exceeding specific daily doses of lovastatin in combination with other medications, and avoiding grapefruit juice. The mentioned interacting agents include strong CYP3A4 inhibitors like ketoconazole, HIV protease inhibitors, nefazodone, and cobicistat-containing products. Other drugs listed are gemfibrozil, cyclosporine, danazol, diltiazem, and dronedarone, with specific recommendations provided for each.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.